文献速递心脑血管急症重症综合管理与镇静镇痛

脑损伤血清标志物可预测院外心脏骤停后的良好神经功能结局

Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest.
PubMed 文献 · Intensive Care Med · 2021-08-21
一句话结论心脏骤停后24至72小时NFL、tau、GFAP正常对6个月良好神经功能结局的阴性预测值达87%–95%,可能有助于避免过早撤除生命支持治疗。

该研究基于TTM试验中717例院外心脏骤停患者前瞻性收集的血清样本进行回顾性分析,检测24、48、72小时的NSE、S100B及新型标志物NFL、总tau、UCH-L1、GFAP,用参考实验室或文献预先设定的正常界值预测6个月良好神经功能结局(CPC 1–2)。正常NFL、tau和GFAP的敏感性最高(97.2%–98%的不良结局患者血清水平异常),NPV为87%–95%;正常S100B和NSE的NPV为76%–82.2%。正常NSE在指南判为「结局不确定」的患者中正确识别67/190(35.3%)例良好结局者。作者结论认为,血液脑损伤标志物低水平与心脏骤停后良好神经功能结局相关,将其纳入神经预后评估可能有助于防止过早撤除生命支持治疗。

要点

  • 717例院外心脏骤停患者中,正常NFL、tau和GFAP预测6个月良好神经功能结局(CPC 1–2)的NPV为87%–95%,敏感性97.2%–98%。
  • 正常S100B和NSE预测良好结局的NPV为76%–82.2%,低于NFL、tau和GFAP。
  • 在指南判为「结局不确定」的患者中,正常NSE正确识别67/190(35.3%)例良好结局者。
  • 5例患者尽管标志物正常但存在单项病理学预后发现,最终仍为良好结局。
  • 作者认为将生物标志物纳入神经预后评估可能有助于防止过早撤除生命支持治疗。

适用人群与场景

  • TTM试验中院外心脏骤停后昏迷的患者,血清样本于骤停后24、48和72小时采集。

诊断标准与关键阈值

  • 良好神经功能结局定义为6个月时无至中度残疾,即脑功能表现分类(CPC)量表1–2分。
  • 采用参考实验室预先设定或文献定义的正常水平界值预测良好结局。

红旗征与不能漏的情况

  • 5例患者标志物正常但存在单项病理学预后发现,最终仍为良好结局,提示单一病理学预后发现不能等同于不良结局。

研究设计与关键结果

  • 研究类型为对TTM试验中前瞻性收集血清样本的回顾性分析,纳入717例患者。
  • 正常NFL、tau和GFAP预测良好结局的敏感性最高:97.2%–98%的不良结局患者血清水平异常,NPV为87%–95%。
  • 正常S100B和NSE预测良好结局的NPV为76%–82.2%。
  • 正常NSE在指南判为「结局不确定」的患者中正确识别67/190(35.3%)例良好结局者。
  • 5例患者尽管标志物正常但存在单项病理学预后发现,最终仍为良好结局。

证据类型、等级与局限

  • 证据类型:对TTM试验中前瞻性收集血清样本的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,将生物标志物纳入神经预后评估可能有助于防止过早撤除生命支持治疗。
  • 正常NFL、tau和GFAP对良好结局的NPV为87%–95%,可能在指南判为「结局不确定」的患者中辅助识别良好结局者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The majority of unconscious patients after cardiac arrest (CA) do not fulfill guideline criteria for a likely poor outcome, their prognosis is considered "indeterminate". We compared brain injury markers in blood for prediction of good outcome and for identifying false positive predictions of poor outcome as recommended by guidelines.

METHODS: Retrospective analysis of prospectively collected serum samples at 24, 48 and 72 h post arrest within the Target Temperature Management after out-of-hospital cardiac arrest (TTM)-trial. Clinically available markers neuron-specific enolase (NSE) and S100B, and novel markers neurofilament light chain (NFL), total tau, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) were analysed. Normal levels with a priori cutoffs specified by reference laboratories or defined from literature were used to predict good outcome (no to moderate disability, Cerebral Performance Category scale 1-2) at 6 months.

RESULTS: Seven hundred and seventeen patients were included. Normal NFL, tau and GFAP had the highest sensitivities (97.2-98% of poor outcome patients had abnormal serum levels) and NPV (normal levels predicted good outcome in 87-95% of patients). Normal S100B and NSE predicted good outcome with NPV 76-82.2%. Normal NSE correctly identified 67/190 (35.3%) patients with good outcome among those classified as "indeterminate outcome" by guidelines. Five patients with single pathological prognostic findings despite normal biomarkers had good outcome.

CONCLUSION: Low levels of brain injury markers in blood are associated with good neurological outcome after CA. Incorporating biomarkers into neuroprognostication may help prevent premature withdrawal of life-sustaining therapy.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Moseby-Knappe M, Mattsson-Carlgren N, Stammet P, et al. Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Med. 2021. PMID: 34417831. doi:10.1007/s00134-021-06481-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。